Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Partners In Health, Abbott and the Abbott Fund Open Nutrition Facility in Haiti

Published: Monday, November 11, 2013
Last Updated: Monday, November 11, 2013
Bookmark and Share
Facility produces first shipments of locally sourced, therapeutic food to treat severe malnutrition in children.

Abbott and Partners in Health combine unique, complementary expertise to build facility, train local team and drive sustainable development.

Partners In Health (PIH), Abbott and its foundation, the Abbott Fund, today announced the opening of a new nutrition production facility in the Central Plateau in Haiti. The centerpiece of a broader partnership between PIH, Abbott and the Abbott Fund to help drive economic development in the region, the facility will produce "Nourimanba," a life-saving treatment for severe malnutrition in children. The first shipments of Nourimanba produced at the new facility have been distributed to PIH's clinics in the region, and are already being used to provide effective treatment for children. 

"After several years of close collaboration, we are excited to achieve this significant milestone in our partnership with Abbott and the Abbott Fund. Producing Nourimanba at the new facility will help PIH and Zanmi Lasante to continue providing free, high-quality treatment for children at our clinics across the region," said Ophelia Dahl, PIH co-founder and executive director. "The impact of this partnership goes well beyond a building. As an employer and a customer for local farmers, this facility aims to spark a cluster of economic activity that is desperately needed in the region."

A New Facility, With a Broader Impact
The 18,000 square-foot Nourimanba Production Facility (Sant Prodiksyon Nourimanba in Haitian Creole) was built primarily by Haitian workers, with technical support from more than 50 Abbott engineers, scientists and other experts. Designed to meet international standards for food products, the facility includes modern laboratories and testing technology, with extensive quality and safety procedures. At the same time, the facility was built to be appropriate for Haiti, with rugged equipment that requires little maintenance.

The facility is operated and managed by Haitians, led by PIH's sister organization, Zanmi Lasante (Partners In Health in Haitian Creole). Abbott and PIH experts provided extensive training for the local team to upgrade manufacturing, production and maintenance skills, and share best practices in quality and food safety. Abbott and PIH also will continue to offer ongoing mentoring and support to ensure long-term sustainable operations.

A Life-Saving Product, Sourced From a Community of Farmers
Even prior to the earthquake in January 2010, one in three Haitian children under the age of five suffered from malnutrition. Nourimanba, a ready-to-use therapeutic food product designed to treat severe childhood malnutrition, is a high-calorie, high-protein, fortified paste that is comprised of only five ingredients: peanuts, milk powder, canola oil, sugar and vitamins. Ready to eat by the patient, Nourimanba does not require mixing with water or refrigeration, and can be given to children at home rather than in a hospital, avoiding the cost and complexity of in-patient treatment. Nourimanba produced at the new facility is provided free to any patient in need through a network of clinics supported by PIH/ZL in the Central Plateau and the Artibonite Valley.

The main ingredient in Nourimanba is locally sourced peanuts grown by Haitian farmers. Through the partnership, a pilot program is providing support for approximately 300 farmers to improve the quality and quantity of the peanut supply needed for the facility, while increasing farmer incomes and the overall competitiveness of the local peanut agricultural sector.

Looking ahead, the partnership is exploring a variety of ways to utilize excess production capacity to produce a fortified peanut butter. Revenue from peanut butter sales would be reinvested in the facility to cover the costs of Nourimanba production, with the goal of creating a social enterprise that will help sustain facility operations over the long term.

Unique Partnership Combines Complementary Expertise, Resources
Partners In Health, Abbott and the Abbott Fund have worked together on the Nourimanba partnership in Haiti since 2009, combining PIH's health care leadership, the skills and knowledge of Zanmi Lasante, more than 10,000 hours of technical support provided by expert Abbott employees, and $6.5 million in funding support from Abbott and the Abbott Fund. 

"When Abbott started working with Partners In Health a few years ago, we were both looking for ways to do things differently, so we can have a greater impact in helping to bring about transformational change in Haiti," said Katherine Pickus, divisional vice president, Global Citizenship and Policy, Abbott, and vice president, the Abbott Fund. "By combining the unique expertise and resources of a non-profit organization and a leading nutrition and healthcare business, and by listening and working closely together every step of the way, we have been able to open a new facility that both produces a life-saving treatment for children and provides economic opportunity for local communities."

The new facility in Haiti builds on prior accomplishments of the ongoing partnership between PIH, Abbott and the Abbott Fund to expand access to health care in developing countries, including establishing a women's health clinic in Lascahobas, Haiti, and building a rural hospital in Malawi. The partnership also is part of Abbott's broader philanthropic work to help address critical health needs in Haiti.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abbott Completes Acquisition of Topera, Inc.
Company acquire all outstanding equity of Topera for $250 million upfront.
Tuesday, January 06, 2015
Abbott to Acquire Veropharm
The acquisition of the Russian pharmaceutical manufacturer is in keeping with the long term commitment to provide healthcare products to Russian patients.
Monday, June 23, 2014
Abbott Completes Separation of Research-Based Pharmaceuticals Business
Set to deliver industry-leading growth, expanding margins and strong cash flow.
Monday, January 07, 2013
Abbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval
HUMIRA is now indicated to treat adult patients with moderate to severe ulcerative colitis who have had an inadequate response to immunosuppressants.
Thursday, October 04, 2012
Abbott to Collaborate with Astellas Pharma
The companies will collaborate in a Phase 3 clinical trial for ASP0113, an investigational vaccine for preventing cytomegalovirus reactivation in transplant patients.
Thursday, September 06, 2012
Leading Agent in the Treatment of Psosiasis
Abbott/Eisai's Humira has emerged on top with major-market sales of more than $1.4 billion in 2011.
Tuesday, August 07, 2012
Abbott Licenses Prostate Cancer Biomarkers
The exclusive license from Stanford University for several novel biomarkers could help develop a molecular diagnostic test that differentiates aggressive from nonaggressive prostate cancer.
Wednesday, April 18, 2012
Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company
Abbott Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012
Thursday, March 22, 2012
Abbott's STARLIMS LIMS Technology to be Installed in FDA Testing Laboratories
FDA will begin implementing the software-based LIMS as part of the agency's initiative to enhance FDA testing laboratories by managing complex processes and analysing the vast amount of information generated.
Thursday, January 19, 2012
Abbott and University of Illinois Establish Center for Nutrition, Learning and Memory
The companies have established the first-ever multi-disciplinary nutrition and cognition research center,. The Center for Nutrition, Learning, and Memory will lead directed and solicited research on the impact of nutrition on learning and memory in the human brain.
Tuesday, December 20, 2011
Abbott and Reata Pharmaceuticals Announce Agreement for Next-Generation Antioxidant Inflammation Modulators
The companies announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata’s portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
Wednesday, December 14, 2011
Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test
Companion diagnostic tests identify specific DNA sequences for cancer immunotherapy antigen.
Tuesday, November 29, 2011
FDA Approves First Supplemental Test for Chagas Disease
The U.S. Food and Drug Administration have approved the first test for use as an additional, more specific test on human serum or plasma specimens found to be positive for antibodies to T. cruzi, which causes Chagas disease, a serious and potentially fatal parasitic infection.
Monday, November 21, 2011
Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in Rheumatoid Arthritis
Abbott have presented results from a pooled analysis of two pivotal HUMIRA(R) (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta. The study looked at inflammation and structural damage of the joints in early and long-standing RA and their relationship with deteriorating physical function in each stage of the disease.
Wednesday, November 17, 2010
Abbott to Collaborate with Pfizer Inc on Companion Diagnostic Test
Collaboration will select patient candidates for novel investigational non-small cell lung cancer therapy.
Friday, August 28, 2009
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Kitchen Utensils Can Spread Bacteria Between Foods
In a recent study researchers found that produce that contained bacteria would contaminate other produce items through the continued use of knives or graters—the bacteria would latch on to the utensils commonly found in consumers' homes and spread to the next item.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Safer, Faster Way To Remove Pollutants From Water
Using nanoparticles filled with enzymes proves more effective than current methods.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Novel Tumor Treatment
In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos has been published.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos